ArticlePLoS computational biology2015
Spatial and functional heterogeneities shape collective behavior of tumor-immune networks.
Article in PLoS computational biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Multiscale mathematical model-informed reinforcement learning optimizes combination treatment scheduling in glioblastoma evolution.Science advances · 2025Article
- Integrating mechanism-based T cell phenotypes into a model of tumor-immune cell interactions.APL bioengineering · 2024Article
- Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.The Journal of pathology · 2024Review
- Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.PLoS computational biology · 2023Article
- Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy.iScience · 2022Article
- Modeling cancer immunoediting in tumor microenvironment with system characterization through the ising-model Hamiltonian.BMC bioinformatics · 2022Article
- The impact of tumor associated macrophages on tumor biology under the lens of mathematical modelling: A review.Frontiers in immunology · 2022Review
- Predicting immune checkpoint inhibitor response with mathematical modeling.Immunotherapy · 2021Article
- The role of tumor heterogeneity in immune-tumor interactions.Cancer metastasis reviews · 2021Review
- A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden.Nature biomedical engineering · 2021Article
- Multi-scale modeling of macrophage-T cell interactions within the tumor microenvironment.PLoS computational biology · 2020Article
- Cancer systems immunology.eLife · 2020Review
- A generalizable data-driven multicellular model of pancreatic ductal adenocarcinoma.GigaScience · 2020Article
- Expression of Monocarboxylate Transporter 1 in Immunosuppressive Macrophages Is Associated With the Poor Prognosis in Breast Cancer.Frontiers in oncology · 2020Article
- Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer.Frontiers in physiology · 2020Article
- Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment.Processes (Basel, Switzerland) · 2019Article
- Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.Journal of mammary gland biology and neoplasia · 2018Review
- Modeling triple-negative breast cancer heterogeneity: Effects of stromal macrophages, fibroblasts and tumor vasculature.Journal of theoretical biology · 2018Article
- Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.Journal of the Royal Society, Interface · 2017Review
- Biologically Relevant Heterogeneity: Metrics and Practical Insights.SLAS discovery : advancing life sciences R & D · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tumor growth involves a dynamic interplay between cancer cells and host cells, which collectively form a tumor microenvironmental network that either suppresses or promotes tumor growth under different conditions. The transition from tumor suppression to tumor promotion is mediated by a tumor-induced shift in the local immune state, and despite the clinical challenge this shift poses, little is known about how such dysfunctional immune states are initiated. Clinical and experimental observations have indicated that differences in both the composition and spatial distribution of different cell types and/or signaling molecules within the tumor microenvironment can strongly impact tumor pathogenesis and ultimately patient prognosis. How such "functional" and "spatial" heterogeneities confer such effects, however, is not known. To investigate these phenomena at a level currently inaccessible by direct observation, we developed a computational model of a nascent metastatic tumor capturing salient features of known tumor-immune interactions that faithfully recapitulates key features of existing experimental observations. Surprisingly, over a wide range of model formulations, we observed that heterogeneity in both spatial organization and cell phenotype drove the emergence of immunosuppressive network states. We determined that this observation is general and robust to parameter choice by developing a systems-level sensitivity analysis technique, and we extended this analysis to generate other parameter-independent, experimentally testable hypotheses. Lastly, we leveraged this model as an in silico test bed to evaluate potential strategies for engineering cell-based therapies to overcome tumor associated immune dysfunction and thereby identified modes of immune modulation predicted to be most effective. Collectively, this work establishes a new integrated framework for investigating and modulating tumor-immune networks and provides insights into how such interactions may shape early stages of tumor formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.